An Open-labelled, Randomized Phase II Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients With GBM Measured as Progression Free Survival Compared to Avastin/Irinotecan
Latest Information Update: 31 Mar 2022
Price :
$35 *
At a glance
- Drugs Cancer vaccine-ALECSAT (Primary) ; Bevacizumab; Irinotecan
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors CytoVac
- 31 Mar 2022 Status changed from discontinued to completed.
- 16 Jun 2015 Planned End Date changed from 1 Mar 2017 to 1 Sep 2015 as per ClinicalTrials.gov.
- 16 Jun 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.